Efficacy of alternative dosing regimens of poly-aggregated amphotericin B

International Journal of Antimicrobial Agents

Volumn 32, Issue 1, 2008, Pages 55-61

  Espada, Raquel ^a   Valdespina, Suriñe ^a   Molero, Gloria ^a   Dea, María A ^a   Ballesteros, María P ^a   Torrado, Juan J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Aggregation state; Amphotericin B; Candida; Dosing; Efficacy; Toxicity

Indexed keywords

AMPHOTERICIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATROPHY; CANDIDA ALBICANS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; FEMALE; INFECTION; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; UREA BLOOD LEVEL;

AMPHOTERICIN B; ANIMAL STRUCTURES; ANIMALS; ANTIFUNGAL AGENTS; ATROPHY; CANDIDA ALBICANS; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; FEMALE; KIDNEY; MICE; MICE, INBRED ICR; PLASMA; SURVIVAL ANALYSIS;

EID: 44949146994     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.02.025     Document Type: Article

References (29)

1. Bates D.W., Su L., Yu D.T., Chertow G.M., Seger D.L., Gomes D.R., et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 60 (2001) 1452-1459
2. Tiphine M., Letscher-Bru V., and Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Transpl Infect Dis 1 (1999) 273-283
3. Kleinberg M. What is the current and future status of conventional amphotericin B?. Int J Antimicrob Agents 27 Suppl. 1 (2006) S12-S16
4. Tancrède P., Barwicz J., Jutras S., and Gruda I. The effect of surfactants on the aggregation state of amphotericin B. Biochim Biophys Acta 1030 (1990) 289-295
5. Gaboriau F., Cheron M., Leroy L., and Bolard J. Physico-chemical properties of the heat-induced 'superaggregates' of amphotericin B. Biophys Chem 66 (1997) 1-12
6. Saka Y., and Mita T. Interaction of amphotericin B with cholesterol in monolayers, aqueous solutions, and phospholipid bilayers. J Biochem 123 (1998) 798-805
7. Ordóñez-Gutiérrez L., Espada-Fernández R., Dea-Ayuela M.A., Torrado J.J., Bolás-Fernandez F., and Alunda J.M. In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum. Int J Antimicrob Agents 30 (2007) 325-329
8. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. Amphotericin B formulations and drug targeting. J Pharm Sci 2007;Sep 24 [Epub ahead of print].
9. Sánchez-Brunete J.A., Dea M.A., Rama S., Bolás F., Alunda J.M., Torrado-Santiago S., et al. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis. J Drug Target 12 (2004) 453-460
10. Sánchez-Brunete J.A., Dea M.A., Rama S., Alunda J.M., Raposo R., Méndez M.T., et al. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 48 (2004) 3246-3252
11. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
12. Clemons K.V., Sobel R.A., Williams P.L., Pappagianis D., and Stevens D.A. Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 46 (2002) 2420-2426
13. Adler-Moore J.P., Olson J.A., and Proffitt R.T. Alternative dosing regimens of liposomal amphotericin B effective in treating murine systemic candidiasis. J Antimicrob Chemother 54 (2004) 1096-1102
14. Gillum A.M., Tsay E.Y., and Kirsch D.R. Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198 (1984) 179-182
15. Londoño P., Gao X.M., Bowe F., McPheat W.L., Booth G., and Dougan G. Evaluation of the intranasal challenge route in mice as a mucosal model for Candida albicans infection. Microbiology 144 (1998) 2291-2298
16. McClelland E.E., Granger D.L., and Potts W.K. Major histocompatibility complex-dependent susceptibility to Cryptococcus neoformans in mice. Infect Immun 71 (2003) 4815-4817
17. Andes D., Safdar N., Marchillo K., and Conklin R. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 50 (2006) 674-684
18. Theiss S., Ishdorj G., Brenot A., Kretschmar M., Lan C.Y., Nichterlein T., et al. Inactivation of the phospholipase B gene PLB5 in wild-type Candida albicans reduces cell-associated phospholipase A2 activity and attenuates virulence. Int J Med Microbiol 296 (2006) 405-420
19. Espada R., Valdespina S., Dea M.A., Molero G., Ballesteros M.P., Bolás F., et al. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. J Antimicrob Chemother 61 (2008) 1125-1131
20. Gondal J.A., Swartz R.P., and Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother 33 (1989) 1544-1548
21. Clark J.M., Whitney R.R., Olsen S.J., George R.J., Swerdel M.R., Kunselman L., et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35 (1991) 615-621
22. Clemons K.V., and Stevens D.A. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother 35 (1991) 1829-1833
23. Espada R., Josa J.M., Valdespina S., Dea M.A., Ballesteros M.P., Alunda J.M., et al. HPLC assay for determination of amphotericin B in biological samples. Biomed Chromatogr 22 (2008) 402-407
24. Bassetti M., Righi E., Costa A., et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6 (2006) 21
25. Bedini A., Venturelli C., Mussini C., et al. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 12 (2006) 75-80
26. Bassetti M., Trecarichi E.M., Righi E., et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 58 (2007) 325-331
27. Rex J.H., Walsh T.J., Sobel J.D., Filler S.G., Pappas P.G., Dismukes W.E., et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 30 (2000) 662-678
28. Clemons K.V., and Stevens D.A. Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob Agents Chemother 42 (1998) 899-902
29. Clemons K.V., and Stevens D.A. Comparative efficacies of four amphotericin B formulations-Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet-against systemic murine aspergillosis. Antimicrob Agents Chemother 48 (2004) 1047-1050